Comparative Pharmacology
Head-to-head clinical analysis: LARYNG O JET KIT versus NOVOCAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARYNG O JET KIT versus NOVOCAIN.
LARYNG-O-JET KIT vs NOVOCAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine, a local anesthetic, stabilizes neuronal membranes by inhibiting sodium ion channels, blocking initiation and conduction of nerve impulses. Epinephrine causes vasoconstriction via alpha-1 adrenergic receptor activation, reducing systemic absorption of lidocaine and prolonging local effect.
Procaine, an ester-type local anesthetic, reversibly binds to the intracellular portion of voltage-gated sodium channels, inhibiting sodium influx and blocking nerve impulse conduction.
Topical administration via laryngeal spray: 1-2 sprays (10-20 mg) to the larynx and pharynx, repeated as needed up to every 1-2 hours, not to exceed 8 sprays per 24 hours.
Local infiltration: 0.5% solution, up to 20 mL (100 mg) per dose; nerve block: 1-2% solution, 5-10 mL (50-200 mg); maximum single dose: 7 mg/kg or 350 mg (without epinephrine).
None Documented
None Documented
Terminal elimination half-life is 1.5–2 hours (mean 1.8 h), necessitating frequent dosing for sustained effect.
Plasma half-life: approximately 30–60 seconds due to rapid hydrolysis by pseudocholinesterases; clinical effects short-lived.
Renal excretion of unchanged drug accounts for approximately 70% of elimination, with 30% undergoing hepatic metabolism and biliary/fecal elimination.
Renal excretion of para-aminobenzoic acid (PABA) and diethylaminoethanol as major metabolites; <2% excreted unchanged in urine. Biliary/fecal: minimal.
Category C
Category C
Local Anesthetic
Local Anesthetic